ENVB - Enveric Biosciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Naples,
United States
Type: Equity
ENVB price evolution
ENVB
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.11 | $3.5 | $6.36 | $2.29 |
| Short term investments | ||||
| Net receivables | $0.02 | $0.3 | $0.46 | |
| Inventory | ||||
| Total current assets | $4.34 | $5.52 | $8.23 | $3.58 |
| Long term investments | ||||
| Property, plant & equipment | $0.37 | $0.41 | $0.45 | $0.51 |
| Goodwill & intangible assets | $0.13 | $0.17 | $0.21 | |
| Total noncurrent assets | $0.53 | $0.62 | $0.72 | |
| Total investments | ||||
| Total assets | $4.79 | $6.05 | $8.85 | $4.3 |
| Current liabilities | ||||
| Accounts payable | $0.58 | $0.46 | $1.85 | $1.22 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $0.84 | $0.65 | $2.37 | $2.34 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $0.84 | $0.65 | $2.37 | $2.34 |
| Shareholders' equity | ||||
| Retained earnings | -$102.92 | -$100.84 | -$98.96 | -$96.5 |
| Other shareholder equity | -$0.54 | -$0.57 | -$0.55 | -$0.57 |
| Total shareholder equity | $5.41 | $6.48 | $1.96 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.29 | $17.72 | $17.36 | $1.58 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $3.58 | $18.43 | $17.74 | $2.28 |
| Long term investments | ||||
| Property, plant & equipment | $0.51 | $0.74 | $0.47 | |
| Goodwill & intangible assets | $0.21 | $0.38 | $8.51 | $1.82 |
| Total noncurrent assets | $0.72 | $1.12 | $8.98 | $1.82 |
| Total investments | ||||
| Total assets | $4.3 | $19.55 | $26.72 | $4.1 |
| Current liabilities | ||||
| Accounts payable | $1.22 | $0.46 | $0.68 | $0.68 |
| Deferred revenue | ||||
| Short long term debt | $0.06 | $0.11 | ||
| Total current liabilities | $2.34 | $4 | $2.08 | $0.68 |
| Long term debt | $0.07 | |||
| Total noncurrent liabilities | $2.33 | |||
| Total debt | $0.06 | $0.18 | ||
| Total liabilities | $2.34 | $4.88 | $4.41 | $0.68 |
| Shareholders' equity | ||||
| Retained earnings | -$96.5 | -$79.21 | -$60.74 | -$11.76 |
| Other shareholder equity | -$0.57 | -$0.54 | -$0.03 | -$0.18 |
| Total shareholder equity | $1.96 | $14.67 | $22.31 | $3.42 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.52 | $0.46 | $1.37 | |
| Selling, general & administrative | $1.3 | $1.93 | $0.93 | |
| Total operating expenses | $1.9 | $2.48 | $2.38 | |
| Operating income | -$1.9 | -$2.48 | -$2.38 | |
| Income from continuing operations | ||||
| EBIT | -$1.88 | -$2.45 | -$3.41 | |
| Income tax expense | $0 | $0.02 | ||
| Interest expense | -$0 | $0 | -$0 | |
| Net income | ||||
| Net income | -$1.88 | -$2.46 | -$3.44 | |
| Income (for common shares) | -$1.88 | -$2.46 | -$3.44 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $7.25 | $8.03 | $4.79 | $0.17 |
| Selling, general & administrative | $8.85 | $11.61 | $20.5 | $5.44 |
| Total operating expenses | $16.45 | $27.42 | $64.62 | $5.62 |
| Operating income | -$16.45 | -$27.42 | -$64.62 | -$5.62 |
| Income from continuing operations | ||||
| EBIT | -$17.27 | -$19.95 | -$56.42 | -$6.42 |
| Income tax expense | $0.03 | -$1.49 | -$7.45 | |
| Interest expense | -$0 | $0.01 | $0.01 | $0.45 |
| Net income | ||||
| Net income | -$17.29 | -$18.47 | -$48.98 | -$6.86 |
| Income (for common shares) | -$17.46 | -$18.8 | -$48.98 | -$6.86 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1.88 | -$2.46 | -$3.44 | |
| Operating activities | ||||
| Depreciation | $0.08 | $0.09 | $0.08 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.37 | $0.35 | $0.36 | |
| Total cash flows from operations | -$2.89 | -$2.6 | -$1.75 | |
| Investing activities | ||||
| Capital expenditures | -$0 | |||
| Investments | ||||
| Total cash flows from investing | -$0 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.05 | $4.13 | ||
| Net borrowings | ||||
| Total cash flows from financing | $7.21 | $0.03 | $6.66 | -$0.19 |
| Effect of exchange rate | $0.03 | $0 | $0.01 | -$0.04 |
| Change in cash and equivalents | $0.82 | -$2.85 | $4.07 | -$1.98 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$17.29 | -$18.47 | -$48.98 | -$6.86 |
| Operating activities | ||||
| Depreciation | $0.41 | $0.44 | $0.68 | $0.12 |
| Business acquisitions & disposals | $3.06 | -$0.04 | ||
| Stock-based compensation | $2.15 | $2.62 | $12.6 | $1.98 |
| Total cash flows from operations | -$14.09 | -$17.15 | -$11.46 | -$3.89 |
| Investing activities | ||||
| Capital expenditures | $0.01 | -$0.58 | -$0.19 | |
| Investments | ||||
| Total cash flows from investing | $0.01 | -$0.58 | $2.19 | -$0.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.22 | $21.61 | $3.86 | |
| Net borrowings | $1.67 | |||
| Total cash flows from financing | -$1.34 | $18.18 | $24.9 | $5.53 |
| Effect of exchange rate | -$0.01 | -$0.08 | $0.14 | -$0.06 |
| Change in cash and equivalents | -$15.44 | $0.37 | $15.78 | $1.53 |
News
Fundamentals
| Market cap | $3.62M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 8.99M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.35 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.20 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.17 |
| Quick ratio | N/A |